Abstract：
Sodium-glucose cotransporter-2 inhibitors have been shown to have significant metabolic, renal, and atherosclerotic cardiovascular disease benefits. Recent randomized controlled trials have extended these benefits to patients with heart failure. In fact, the robust findings from these studies in patients with any type of heart failure have led to the incorporation of this drug class in currently updated evidence-based guidelines for this condition. However, given the novelty in utilizing these agents in heart failure, there is uncertainty regarding place in therapy and sequencing in treatment. As such, this review aims to summarize existing literature to guide practitioners regarding the use of these agents in the management of heart failure.
摘要：
钠-葡萄糖协同转运蛋白-2抑制剂已被证明具有显著的代谢，肾,和动脉粥样硬化性心血管疾病的好处。最近的随机对照试验将这些益处扩展到心力衰竭患者。事实上,这些研究对任何类型心力衰竭患者的有力发现导致该药物被纳入目前针对该疾病的最新循证指南.然而,考虑到在心力衰竭中使用这些药物的新颖性，在治疗中的位置和治疗中的排序存在不确定性.因此，本综述旨在总结现有文献,以指导从业人员在心力衰竭治疗中使用这些药物.
